Kennedy Says FDA Reviewing Safety of Abortion Pill Mifepristone
MONDAY, Sept. 29, 2025 — The U.S. Food and Drug Administration (FDA) is reviewing the safety of mifepristone, a drug used in medication abortions for 25 years, amid a push from conservative state attorneys general and anti-abortion groups.
The announcement was made in a letter from Health and Human Services Secretary Robert F. Kennedy Jr, according to CBS News.
The review, spearheaded by Kennedy, focuses on compliance with an FDA safety program aimed at ensuring a drug’s benefits outweigh its risks. He said it will review “the latest data” and "real-world outcomes and evidence" related to the drug's safety and effectiveness.
The review follows action in 2023 by the Biden administration allowing patients to receive mifepristone by mail and through telehealth appointments. Conservatives have criticized the move. A majority of abortions in the U.S. are now done using medication, with mifepristone being the first of a two-drug regimen.
The letter from Kennedy cited a study by the Ethics and Public Policy Center (EPPC) that suggested "potential dangers that may attend offering mifepristone without sufficient medical support or supervision." The letter also mentioned FDA data, which reported 2,740 adverse events from 2000 to 2012, including 416 requiring blood transfusions, CBS News reports.
The EPPC study said nearly 11% of women experience a serious adverse event. Other sources contest that figure.
"Other data sources show the rate of serious complications to be much lower, at less than 1 in 200," CBS News medical contributor Dr. Céline Gounder said.
Advocates for the drug’s use insist it has a strong safety record.
"More than 100 studies confirm mifepristone's exceptional safety record," the American Civil Liberties Union (ACLU) said in a statement. It noted that the drug has been used by more than 7.5 million women since its initial FDA approval in 2000. It is approved to terminate pregnancy through 10 weeks of gestation.
While the review could lead to changes in how the drug is prescribed, such as limiting its availability through telehealth or to certain types of health care providers, experts suggest an outright ban is unlikely.
Gounder said it would be "an extraordinary step" for the FDA to withdraw its approval for mifepristone and would likely face immediate legal challenges.
While Kennedy's letter did not provide a timeline for completion of the review, he said the FDA would keep states informed of its progress.
Sources
- CBS News, Sept. 26, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Frozen Meals Sold at 3 Chains Linked to Listeria Outbreak
MONDAY, Sept. 29, 2025 — Federal health officials have expanded their probe into a listeria outbreak that has claimed four lives, and affected at least 20 people. The...
Hidden Signs Of Rheumatoid Arthritis Found In Blood Long Before Diagnosis
MONDAY, Sept. 29, 2025 — An invisible storm might rage for years inside the bodies of people at risk for rheumatoid arthritis, prior to any joint pain occurring, a new study...
Golf Cart Injuries On The Rise Among Kids
MONDAY, Sept. 29, 2025 — More kids are being hurt in golf cart accidents, a new study says. Golf cart injuries among children have steadily increased over the past three...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.